H. McAllister-Williams, United Kingdom

Newcastle University Mental Health, Dementia and Neurodegenerative Disorders
Prof McAllister-Williams obtained his qualification in medicine, and a PhD in Neuropharmacology, at the University of Edinburgh, Scotland. He moved to Newcastle University, England, in 1995 and was awarded a UK Medical Research Council Clinician Scientist Fellowship to investigate the pathophysiology of affective disorders, completing a research MD degree. In 2004 he was appointed a Reader in Clinical Psychopharmacology and then in 2017 Professor of Affective Disorders. He is the Lead for the Mental Health, Dementia and Neurodegenerative Disorders Research Theme. Clinically, he leads a tertiary level specialist affective disorders service in the Cumbria, Northumberland Tyne and Wear NHS Foundation Trust.

Presenter of 4 Presentations

LIVE - Symposium: Difficult to Treat Depression (ID 270) No Topic Needed

Live Q&A

Session Icon
Live
Date
Tue, 13.04.2021
Session Time
10:00 - 11:30
Room
Channel 1
Lecture Time
11:08 - 11:28
LIVE - Symposium: When East Meets West, the Treatment of Depression is at its Best (ID 1174) No Topic Needed
LIVE - Symposium: When East Meets West, the Treatment of Depression is at its Best (ID 1174) No Topic Needed

An Overview of Western Treatment Options for Difficult to Treat Depression

Session Icon
Live
Date
Sat, 10.04.2021
Session Time
07:00 - 08:00
Room
Plenary
Lecture Time
07:20 - 07:30
LIVE - Symposium: Difficult to Treat Depression (ID 270) No Topic Needed

S0151 - A Model for the Management of Difficult to Treat Depression

Session Icon
Live
Date
Tue, 13.04.2021
Session Time
10:00 - 11:30
Room
Channel 1
Lecture Time
10:34 - 10:51

ABSTRACT

Abstract Body

In this presentation a model for the management of difficult to treat depression (DTD) will be presented based upon a recently published international consensus statement (McAllister-Williams et al. 2020 Journal of Affective Disorders 267:264-282). This model emphasises the goals of: optimal symptom control – remission if possible; optimisation of psychosocial functioning; and optimisation of prophylaxis against relapse/deterioration in mood. Building on these goals, the model follows a number of principles. These include emphasizing the importance of shared decision making and measurement-based care, enhancing engagement and retention in services, self-management strategies and frequent re-assessments, all incorporated in an integrated service pathway. The model itself encompasses eight elements: 1. Optimal symptom control using conventional, guideline recommended, treatments but moving on to treatments beyond guidelines in an appropriate and timely way; 2. Targeting symptoms associated with poor outcomes, e.g. anxiety and pain; 3. Targeting symptoms associated with poor functioning and quality of life such as sleep difficulties, fatigue and cognitive dysfunction; 4. Screening for and managing physical, psychiatric, substance misuse and iatrogenic comorbidities; 5. Optimisation of long-term treatment; 6. Using self-management techniques to empower patients; 7. Using integrated health services to help provide a sense of containment and ensure wide consideration of treatment options; and 8. Establishing regular reviews of the patient’s diagnosis and treatment. Examples of each of these elements will be provided.

Hide